Breast Cancer Outcome Details (Form 122/130), CaD ppts
| File Name | Data as of | Population | Data collected | One row per | Rows |
|---|---|---|---|---|---|
| outc_bc_cad_inv.dat | 2/17/2024 | CaD | Main, Ext1 | Outcome Form | 2,203 |
ID - WHI Participant Common ID Col 1
ASCSOURCE - Ascertainment Source Col 2
BREASTINV - Breast Cancer Invasive Col 3 Usage Notes: Defined as a breast cancer from a Death or the first adjudication where the form 122 or 130 details indicate an invasive cancer. Breast Cancer Invasive is adjudicated for CT and OS participants. WHI adjudicated all reports of breast cancer for a ppt until the first invasive Breast Cancer. i.e. The first Invasive Breast Cancer may not be the first Breast Cancer. This file does not include cancers determined solely by the cause of death.
BREASTINSITU - Breast Cancer In Situ Col 4 Usage Notes: Defined as the first breast cancer where the form 122 or 130 details indicate an in situ cancer. Breast Cancer In Situ is adjudicated for CT and OS participants. Breast Cancer In Situ occurring on or after a Breast Cancer Invasive is not counted.
ICDCODE - ICD-O-2 site code Col 5 Usage Notes: All centrally adjudicated cancers (F130) have an ICD-O-2 code. The only locally adjudicated cancers with a code are those marked as "other" on F122. F122 codes do not include a decimal. See the SEER coding section of the data prep/use document for details. A description of the ICD site codes can be found in the reference file seer_icd_site_codes.dat by merging on the ICDCODE variable.
BEHAVIOR - Tumor Behavior Col 6 Usage Notes: For cancers that have been SEER coded, tumor behavior comes from the 5th digit of the morphology (see MRPHHISTB). For cancers that have not been SEER coded, F130/Question 3 or F122/Question 4 is used.
RPRTSRC - Reporting source Col 7 Reporting Source: (Mark only one. If more than one category applies, mark the first applicable category.)
DIAGSTAT - Diagnostic confirmation status Col 8 Diagnostic Confirmation Status: (Mark only one. If more than one category applies, mark the first applicable category.)
LATERAL - Laterality Col 9
MRPHHISTB - Morphology - hystology/behavior Col 10 Morphology first 5 digits Usage Notes: ICD-O-2 codes were used for all cancers except Lymphoma and Leukemia. WHI used ICD-O-3 codes for those cancers. WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details. A description of the histology/behavior codes can be found in the reference file seer_icd_hist_codes.dat by merging on the MRPHHISTB variable.
GRADING - Morphology - grading Col 11 Morphology: 6th digit Usage Notes: WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.
SIZE - F130 EOD SEER - Size Col 12 Evidence of Disease (SEER):first section Usage Notes: When size doesnt make sense, this field is used for other purposes (e.g. Leukemias have no size, this field records AIDS status). Size is usually measured in mm, though it may vary by cancer type. Even for cancers that do have a size, not all values indicate an actual size (e.g. 2 for many cancers means "<=2mm", but for breast cancer it means "Mammographic diagnosis only, tumor not clinically palpable" ). WHI used the SEER 1988, 2nd edition rules for coding cancers. See the SEER coding section of the data prep/use document for details.
EXTENSION - F130 EOD SEER - Extension Col 13 Evidence of Disease (SEER): digits 4-5 Usage Notes: WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.
INVOLVE - F130 EOD (SEER) - Lymph node involvement Col 14 Evidence of Disease (SEER): digit 6 Usage Notes: WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.
POSLYMPH - F130 EOD (SEER) - Number of positive lymph nodes Col 15 Evidence of Disease (SEER): digits 7-8 Usage Notes: WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.
NUMLYMPH - F130 EOD (SEER) - Number of lymph nodes examined Col 16 Evidence of Disease (SEER): digits 9-10 Usage Notes: WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.
STAGE - Summary Stage (SEER) Col 17 Usage Notes: WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.
HIST8522 - F130 Breast Histology 8522 Subclass Col 18 Subclassification for Breast Histology 8522. Usage Notes: Not collected on early versions of F130.
ERASSAY - F130 Estrogen receptor assay Col 19
ERDY - F130 Days to Estrogen Assay Col 20
ERTYPE - F130 Type of Estrogen Assay Col 21
PRASSAY - Progesterone receptor assay Col 22
PRDY - F130 Days to Progesterone receptor assay Col 23
PRTYPE - F130 Type of Progesterone receptor assay Col 24
HER2NEU - F130 Her 2/Neu Col 25 Usage Notes: Not collected on early versions of F130.
HER2NEUDY - F130 Days to HER 2/NEU Col 26 Usage Notes: Not collected on early versions of F130.
AGEDX - Age at diagnosis Col 27
|
This file has one row for every form 122 or 130 recording in situ or invasive breast cancer outcome(s). A participant may have more than one of these forms. Only the first occurrence of each outcome is counted, e.g. Limiting the file to rows where BREASTINV=1 will find a single row for each participant with a invasive breast cancer outcome. Breast Cancers derived solely from a cause of death do not have an associated form 122 or 130 so are not included. File contains outcomes through Ext1.